



AHCL/ SE/ 45 /2022-23

February 14, 2023

| | |
|---|--|
| The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031 | BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 |
| Symbol : AMRUTANJAN | Scrip Code: 590006 |

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**February 14, 2023**) had inter-alia:

- (i) Approved the Un-Audited Financial Results for the quarter ended December 31, 2022. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.1/- per share for the financial year 2022-23 on the Equity Shares of the Company.

The Board Meeting commenced at 01.00 PM and concluded at 06.15 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(M Srinivasan)
Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter and nine months ended December 31 2022.
2. Limited Review Report

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of unaudited Financial Results for the quarter and nine months ended 31 December 2022

| | | Quarter ended | | | Period ended | | (Rs. in Lakhs) |
|-------------|---|---------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------|
| Particulars | | 31 December 2022 (Unaudited) | 30 September 2022 (Unaudited) | 31 December 2021 (Unaudited) | 31 December 2022 (Unaudited) | 31 December 2021 (Unaudited) | 31 March 2022 (Audited) |
| I | Revenue from operations | 9,764.55 | 11,071.93 | 11,069.59 | 27,931.91 | 29,928.94 | 40,584.24 |
| II | Other income | 367.75 | 303.24 | 319.83 | 972.23 | 1,022.23 | 1,538.25 |
| III | Total Income (I + II) | 10,132.30 | 11,375.17 | 11,389.42 | 28,904.14 | 30,951.17 | 42,122.49 |
| IV | Expenses | | | | | | |
| | (a) Cost of materials consumed | 2,754.73 | 2,880.17 | 3,004.76 | 8,308.10 | 8,739.89 | 12,186.02 |
| | (b) Purchases of stock-in-trade | 1,612.67 | 2,203.46 | 1,717.37 | 5,155.73 | 4,636.72 | 6,410.22 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (173.50) | 311.78 | (41.68) | (375.65) | (334.96) | (549.99) |
| | (d) Employee benefits expense | 1,201.93 | 1,231.15 | 1,159.67 | 3,644.06 | 3,592.50 | 4,822.90 |
| | (e) Advertisement and selling expenditure | 1,988.02 | 1,567.42 | 1,972.35 | 4,544.63 | 4,646.95 | 5,503.26 |
| | (f) Finance cost | 1.59 | 1.95 | 2.98 | 5.99 | 18.37 | 48.45 |
| | (g) Depreciation and amortisation expense | 131.41 | 152.06 | 87.72 | 390.17 | 260.22 | 379.52 |
| | (h) Other expenses | 1,165.12 | 1,285.12 | 694.75 | 3,513.67 | 2,335.75 | 4,264.45 |
| | Total expenses (IV) | 8,681.97 | 9,633.11 | 8,597.92 | 25,186.70 | 23,895.44 | 33,064.83 |
| V | Profit before tax (III - IV) | 1,450.33 | 1,742.06 | 2,791.50 | 3,717.44 | 7,055.73 | 9,057.66 |
| VI | Tax expenses | 379.26 | 465.56 | 733.72 | 1,003.47 | 1,807.43 | 2,338.77 |
| VII | Profit after tax (V - VI) | 1,071.07 | 1,276.50 | 2,057.78 | 2,713.97 | 5,248.30 | 6,718.89 |
| VIII | Other comprehensive income | | | | | | |
| | Items that will not be reclassified subsequently to profit or loss | | | | | | |
| | Re-measurement gain/(loss) on defined benefit plans, net of taxes | (0.27) | (45.97) | (24.24) | (118.83) | (66.56) | (63.84) |
| | Other comprehensive income/ (loss) for the period, net of taxes | (0.27) | (45.97) | (24.24) | (118.83) | (66.56) | (63.84) |
| IX | Total comprehensive income for the period (VII + VIII) | 1,070.80 | 1,230.53 | 2,033.54 | 2,595.14 | 5,181.74 | 6,655.05 |
| | Paid-up equity share capital (Face value Re. 1/- each) | 292.31 | 292.31 | 292.31 | 292.31 | 292.31 | 292.31 |
| | Earnings per equity share for continuing operations | | | | | | |
| | Basic earnings per share (INR) | 3.67 | 4.37 | 7.05 | 9.30 | 17.97 | 23.05 |
| | Diluted earnings per share (INR) | 3.66 | 4.36 | 7.03 | 9.29 | 17.92 | 23.03 |
| | | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (annualised) |
| | <i>See accompanying notes to financial results</i> | | | | | | |



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

- The above unaudited financial results for the quarter and nine months ended 31 December 2022 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 14 February 2023. The above results have been subjected to limited review by the statutory auditors of the Company.
- These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company.
- During the quarter and nine months ended 31 December 2022, the Company received a anonymous whistle blower complaint ("compliant") alleging lapses by certain senior management employees including undue enrichment through marketing, advertising and procurement activities, ethical concerns and conflict of interest etc. Pending the completion of the independent investigation being carried out by external agency on these lapses, the management is unable to determine the possible impact on the unaudited financial results, if any, and hence no adjustments have been made to the unaudited financial results for any such lapses that may have taken place. The auditors have qualified their limited review report in this regard.
- Interim Dividend of Re. 1/- per share, aggregating to INR 292.31 Lakhs has paid during the quarter ended 31 December 2022.
- The unaudited financial results of the Company for the quarter and nine months ended 31 December 2022 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com
- Segment reporting in the unaudited financial results: Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

| Particulars | Quarter ended | | | Period ended | | Year ended |
|--|---------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------|
| | 31 December 2022 (Unaudited) | 30 September 2022 (Unaudited) | 31 December 2021 (Unaudited) | 31 December 2022 (Unaudited) | 31 December 2021 (Unaudited) | 31 March 2022 (Audited) |
| 1 Segment revenue | | | | | | |
| a OTC Products | 9,351.22 | 10,423.37 | 10,648.32 | 26,015.95 | 27,814.14 | 37,221.24 |
| b Beverages | 365.23 | 600.28 | 379.74 | 1,761.91 | 2,001.08 | 3,190.46 |
| c Others | 48.10 | 48.28 | 41.53 | 154.05 | 113.72 | 172.54 |
| Total | 9,764.55 | 11,071.93 | 11,069.59 | 27,931.91 | 29,928.94 | 40,584.24 |
| 2 Segment results | | | | | | |
| a OTC Products | 1,368.12 | 1,704.77 | 2,581.91 | 3,515.12 | 6,280.82 | 8,288.14 |
| b Beverages | (136.34) | (223.55) | (35.05) | (503.35) | 86.10 | (7.09) |
| c Others | (20.77) | (18.77) | (22.29) | (82.72) | (82.72) | (96.57) |
| Total | 1,211.01 | 1,462.45 | 2,524.57 | 2,958.77 | 6,284.20 | 8,184.48 |
| Less: Finance cost | 1.59 | 1.95 | 2.98 | 5.99 | 18.37 | 48.45 |
| Add : Other unallocable expenditure net of interest income | 240.91 | 281.56 | 269.91 | 764.66 | 789.90 | 921.63 |
| Total profit before tax | 1,450.33 | 1,742.06 | 2,791.50 | 3,717.44 | 7,055.73 | 9,057.66 |
| 3 Segment assets | | | | | | |
| a OTC Products | 9,290.29 | 10,486.91 | 6,998.04 | 9,290.29 | 6,998.04 | 9,091.91 |
| b Beverages | 2,213.17 | 2,325.41 | 1,876.82 | 2,213.17 | 1,876.82 | 2,073.42 |
| c Others | 44.10 | 52.13 | 73.55 | 44.10 | 73.55 | 65.43 |
| d Unallocated assets | 24,203.19 | 24,006.25 | 23,167.59 | 24,203.19 | 23,167.59 | 23,756.05 |
| Total | 35,750.75 | 36,870.70 | 32,116.00 | 35,750.75 | 32,116.00 | 34,986.81 |
| 4 Segment liabilities | | | | | | |
| a OTC Products | 6,683.48 | 7,187.78 | 5,310.12 | 6,683.48 | 5,310.12 | 5,492.11 |
| b Beverages | 384.62 | 977.78 | 463.96 | 384.62 | 463.96 | 1,812.52 |
| c Others | 43.25 | 51.83 | 70.84 | 43.25 | 70.84 | 68.28 |
| d Unallocated liabilities | 547.48 | 1,355.17 | 711.75 | 547.48 | 711.75 | 1,101.52 |
| Total | 7,658.83 | 9,572.56 | 6,556.67 | 7,658.83 | 6,556.67 | 8,474.43 |
| Total capital employed in the Company | 28,091.92 | 27,298.14 | 25,559.33 | 28,091.92 | 25,559.33 | 26,512.38 |

For Amrutanjan Health Care Limited


S Sambhu Prasad
 Chairman & Managing Director
 DIN: 00015729

Date: 14 February 2023
 Place: Chennai

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floors,
No.1, Harrington Road, Chetpet,
Chennai – 600 031, India

Telephone +91 44 4608 3190
Fax +91 44 4608 3199

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Amrutanjan Health Care Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement") (in which are included unaudited interim financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP Trust"))
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We draw attention to Note 4 to the unaudited financial results of the Company for the quarter and nine months ended 31 December 2022 with respect to a complaint received by the Company. Pending the completion of the independent investigation being carried out by external agency in respect of such complaint, we are unable to determine the likely outcome of the above matter and its impact on the unaudited financial results of the current and earlier periods. Consequently, we were unable to determine whether any adjustments, if any, were necessary to these unaudited financial results.
5. Based on our review conducted as above, except for the possible effects of the matters described in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office

Limited Review Report (Continued)
Amrutanjan Health Care Limited

6. The Statement includes the unaudited interim financial results of ESOP Trust which has not been reviewed, whose unaudited interim financial results reflect total assets of INR 451.87 Lakhs as at 31 December 2022, total revenues of INR 1.71 Lakhs and total loss after tax of INR 0.18 Lakhs for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. According to the information and explanations given to us by the management, these unaudited interim financial results are not material to the Company.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248WW-100022



K Raghuram
Partner

Membership No.: 211171

UDIN:23211171BGYHIM1531

Chennai

14 February 2023